HIV proteinase inhibitors: do they really work against Candida in a clinical setting?

This publication has 12 references indexed in Scilit:

• Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitution–Independent Beneficial Effect onCandidaVirulence and Oral Candidiasis in Human Immunodeficiency Virus–Infected Subjects
  The Journal of Infectious Diseases, 2002
• Growth Inhibition ofCandidaby Human Oral Epithelial Cells
  The Journal of Infectious Diseases, 2000
• Initial Therapy with Protease Inhibitor-Sparing Regimens: Evaluation of Nevirapine and Delavirdine
  Clinical Infectious Diseases, 2000
• Effects of the Human Immunodeficiency Virus (HIV) Proteinase Inhibitors Saquinavir and Indinavir on In Vitro Activities of Secreted Aspartyl Proteinases of Candida albicans Isolates from HIV-Infected Patients
  Antimicrobial Agents and Chemotherapy, 1999
• In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors
  The Journal of Infectious Diseases, 1999
• Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
• Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro
  Immunopharmacology, 1999
• Evidence that Members of the Secretory Aspartyl Proteinase Gene Family, in ParticularSAP2,Are Virulence Factors forCandidaVaginitis
  The Journal of Infectious Diseases, 1999
• CD4+ T-helper-cell responses in mice with low-level Candida albicans infection
  Infection and Immunity, 1996
• Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis
  Infection and Immunity, 1995